Pharma News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • AI could help improve early detection of interval breast cancers
    6 May 2025

    AI could help improve early detection of interval breast cancers

    A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers — those that develop between routine screenings — before they become more advanced and harder to treat. This could potentially lead to better screening practices, earlier treatment and improved patient outcomes.
  • 5 May 2025
    Antivenom neutralizes the neurotoxins of 19 of the world’s deadliest snakes
    By using antibodies from a human donor with a self-induced hyper-immunity to snake venom, scientists have developed the most broadly effective antivenom to date, which is protective against the likes of the black mamba, king cobra, and tiger snakes in mouse trials.
  • 5 May 2025
    Super strong antibodies developed by scientists for new cancer treatment

    Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune systems of patients fighting the disease.

  • 5 May 2025
    Biocon Biologics has secured multiple market access agreements for biosimilar to Stelara
    Biocon Biologics Ltd , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access agreements for Yesintek™, its biosimilar to Stelara®. The market access agreements from numerous plans represent over 100+ million lives in the United States.
  • 1 May 2025
    Novartis to acquire Regulus Therapeutics and farabursen
    Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen.
  • 1 May 2025
    Largest Osteoarthritis Genetic Study Uncovers Pathways to New Therapies and Repurposed Drugs
    Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis. The research, which analyzed data from nearly 2 million people in diverse populations worldwide, was recently published in Nature. It represents an extensive genetic exploration of osteoarthritis, a condition affecting over 600 million people globally.
  • 1 May 2025
    Long-term survival rates of some Acute Myeloid Leukaemia patients could double with sensitive bone marrow test
    A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia by helping doctors identify if they might relapse up to three months earlier. The patient-specific molecular test can detect low levels of leukaemia cells in the body, known as minimal residual disease, which when left untreated causes the disease to relapse.
  • 1 May 2025
    India has to wait for Sanofi Meningitis vaccine
    Sanofi Healthcare India has submitted the application for grant of permission to import Meningococcal vaccine but the subject expert committee of CDSCO requires further information to grant permission.
  • 25 April 2025
    In-Cosmetics, Global held in Amsterdam, Nederlands

    In-Cosmetics Global, the world’s largest conference and exhibition for the cosmetics industry took place from 8th to 10th April 2025 in Amsterdam at RAI Exhibition Center. In-Cosmetics Global is truly, well, global as the event had most of the world’s top personal care ingredient suppliers as well as niche companies making waves in the industry.

    Attendees were from all over the world. Europe accounted to almost 60% of attendees, followed by Asia Pacific, South Central America, and North America and Middle East & Africa.

  • 23 April 2025
    Human Mixtard penfill to be replaced with injectables, Novo Nordisk clarifies
    Novo Nordisk is now discontinuing its Human Mixtard penfill by the year's end. However Mixtard in India will continue to be available in vials. Along with it, other forms of insulin including human insulin from Novo Nordisk will continue to be available in vials & devices for patients across India.
Subscribe to Pharma News